NovaDel Pharma's Third Foreign Patent Issued

Name	Symbol	Market	Type
GraniteShares ETF Trust GraniteShares	NASDAQ:NVDL	NASDAQ	Exchange Traded Fund

Name

Symbol

Market

Type

GraniteShares ETF Trust GraniteShares

NASDAQ:NVDL

NASDAQ

Exchange Traded Fund

	Price Change	% Change	Price	Bid Price	Offer Price	High Price	Low Price	Open Price	Traded	Last Trade
	-1.77	-4.51%	37.5291	37.51	37.53	40.2699	37.62	39.35	16,223,630	23:50:34

Price Change

% Change

Price

Bid Price

Offer Price

High Price

Low Price

Open Price

Traded

Last Trade

-1.77

-4.51%

37.5291

37.51

37.53

40.2699

37.62

39.35

16,223,630

23:50:34

NovaDel Pharma's Third Foreign Patent Issued

22/04/2004 2:29pm

PR Newswire (US)

GraniteShares ETF Trust ... (NASDAQ:NVDL)
Historical Stock Chart

From Mar 2020 to Mar 2025

Click Here for more GraniteShares ETF Trust ... Charts.

NovaDel Pharma's Third Foreign Patent Issued FLEMINGTON, N.J., April 22 /PRNewswire-FirstCall/ -- NovaDel Pharma Inc. (BULLETIN BOARD: NVDL) said it was awarded Greek Patent No.GR0904055 covering its linqual spray drug delivery technology for non-polar products. NovaDel's technology is widely applicable to a variety of drugs for which fast onset of therapeutic activity and reduction of first pass hepatic toxicity are consideration key product attributes. "This patent, which is our third issued internationally, joins five issued US patents in broadening our IP assets," said Gary A. Shangold, MD, chief executive officer of NovaDel. "We currently have 29 patent applications pending in the US, Canada, the EU and Japan, concerning methods of delivery of a variety of therapeutic classes and specific drugs within those classes." About NovaDel Pharma Inc. NovaDel Pharma Inc. is a specialty pharmaceutical company engaged in the development of novel drug delivery systems for prescription and over-the-counter drugs. The Company's proprietary lingual spray technology delivery system offers the patient (i) fast onset of action; (ii) improved drug safety by reducing the required drug dosage and reducing side effects; (iii) improved patient convenience and compliance; and (iv) enhanced dosage reliability. The Company plans to develop such products independently and through collaborative arrangements with major pharmaceutical and biotech companies. Except for historical information contained herein, this document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve known and unknown risks and uncertainties that may cause the Company's actual results or outcomes to be materially different from those anticipated and discussed herein including, but not limited to, the ability to develop products (independently and through collaborative arrangements), and the ability to commercialize and obtain approval for products under development. Further, the Company operates in industries where securities may be volatile and may be influenced by regulatory and other factors beyond the Company's control. Important factors that the Company believes might cause such differences are discussed in the risk factors detailed in the Company's most recent Annual Report and Registration Statements, filed with the Securities and Exchange Commission. In assessing forward-looking statements contained herein, if any, the reader is urged to carefully read all cautionary statements contained in such filings. Contact: Barry C. Cohen VP Business & New Product Development 908 782-3431 x 2160 NovaDel Pharma Inc. Thomas Redington 203 222-7399 212 926-1733 DATASOURCE: NovaDel Pharma Inc. CONTACT: Barry C. Cohen, VP Business & New Product Development of NovaDel Pharma Inc., +1-908-782-3431, ext. 2160; or Thomas Redington, +1-203-222-7399, or +1-212-926-1733, or , for NovaDel Pharma Inc.

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

NVDL GraniteShares ETF Trust GraniteShares